#IAS25: WHO adds Gilead’s twice-yearly injection to global PrEP guidelines

Gilead's twice-yearly HIV prevention injection has been added to global PrEP guidelines by the World Health Organization, weeks after its FDA approval. This significant endorsement is expected to broaden the drug's market reach and adoption, particularly in regions prioritizing scalable HIV prevention strategies.

Analysis

Gilead Sciences (GILD) has secured a significant regulatory and commercial milestone with the World Health Organization (WHO) recommending its twice-yearly HIV prevention injection for inclusion in global PrEP guidelines. This endorsement follows a recent watershed approval from the U.S. Food and Drug Administration (FDA), creating powerful momentum for the product's global rollout. The WHO's recommendation is critical for broader international adoption, particularly in public health programs and markets outside the U.S., as it validates the drug's efficacy and safety profile on a global scale. This dual validation from two leading health authorities solidifies the drug's position as a potential new standard of care in HIV prevention, offering a substantial improvement in convenience and adherence over existing daily oral therapies. The development is a major positive catalyst for Gilead's HIV franchise, expanding its market opportunity and reinforcing its leadership in the space.

Key Decisions for Investors

• The WHO endorsement significantly enhances the global revenue potential for Gilead's long-acting HIV injectable, supporting a bullish outlook on the company's long-term growth trajectory within its HIV franchise.
• Investors should monitor initial uptake figures and national-level procurement decisions following the WHO guidelines, as these will be key indicators of the drug's commercial ramp-up and market penetration.
• This development solidifies Gilead's competitive moat in the HIV prevention market, and positions with a long-term horizon should factor in this new, durable revenue stream.